When a person is confirmed with a diagnosis of breast cancer, one of the first questions is usually: How is a personalized treatment decided in patients with breast cancer? The answer does not depend on a single piece of information: it is constructed with information about the tumour, the general state of health and what the patient considers important for her daily life. With this scenario, the oncology team is looking for a treatment plan that controls the disease with the least possible impact on side effects.
The current approach combines clinical data, laboratory tests and imaging, and clear conversations with the patient. The goal is for each step to make sense for that particular case, whether it’s a localized treatment, systemic therapy, or a combination of surgery, chemotherapy, radiation therapy, and targeted therapies.
Clinical factors that guide the choice of treatment
Tumor stage and extent of disease
The stage indicates how localized the breast cancer is or if it has already spread.
In the early stages, management usually focuses on checking the tumor in the breast and evaluating lymph nodes. In advanced stages, systemic treatments are thought of more strongly because there is a greater risk of disease outside the original site.
Stage definition includes tumor size, lymph node involvement, and whether metastasis is present. This classification influences the order of treatment (e.g., surgery first or neoadjuvant therapy) and the intensity of systemic therapy.
Age, general health status and comorbidities
Age alone doesn’t decide the plan, but it does guide how well chemotherapy, certain radiation therapy regimens, or more extensive surgery can be tolerated. In Panama, as in any place, the patient’s real condition is assessed: heart, kidney and liver function, and presence of comorbidities.
Diseases such as diabetes or heart problems can limit options and force you to adjust doses, select drugs with a different toxicity profile or prioritize support measures to reduce side effects.
Patient Preferences and Goals
Treatment is not only “what can be done”, it is also “what the patient wants and can sustain”. Some prioritize keeping the breast with a lumpectomy if it is safe; others feel more at ease with a mastectomy. Issues such as fertility, work, family care and the level of risk that the patient is willing to assume also weigh in.
An honest conversation about benefits, risks, and expectations helps align treatment with personal values and a realistic quality of life along the way.
Biomarkers and molecular tests that change strategy
Hormone receptors: estrogen and progesterone
Knowing if the tumor has hormone receptors (hormone receptors) is key. When they are positive, there is usually the option of hormone therapy, which in many cases is effective and better tolerated than chemotherapy. According to the National Cancer Institute, about 80% of cases are hormone receptor-positive.
This also influences the duration of treatment and follow-up, since some hormonal tumors may require hormone therapy for several years to lower the risk of relapse.
HER2 Status and Its Impact on Treatment Choice
The HER2 study allows the detection of tumors that overexpress this protein, present in about 15-20% of cases. When HER2 is positive, targeted therapies that block that pathway are considered. This can change the prognosis and also the order of treatment, especially in stages where it is advisable to measure response with neoadjuvant therapy.
In practice, HER2 helps define whether chemotherapy is combined with targeted therapies, and how long treatment is maintained after surgery.
Genetic testing and tumor profiling
Genomic testing looks at several genes in the tumor and helps estimate the risk of recurrence and the potential benefit of chemotherapy. In selected patients, these tests support decisions such as avoiding chemotherapy without compromising breast cancer control.
The value of these tests is in fine-tuning the plan: not all patients with the same stage need the same intensity of systemic therapy.
How a treatment plan is organized according to the stage
Treatment of Stage I and II Breast Cancer
Surgery as an initial treatment
In early stages, surgery is usually the first step. It can be a lumpectomy (conservative surgery) if it is safe from an oncological point of view, or a mastectomy when the case requires it.
Lymph node evaluation is done with sentinel node biopsy or, depending on the findings, with broader procedures. Sentinel node biopsy seeks to reduce complications by avoiding unnecessary surgeries and accurately targeting the rest of the treatment.
Systemic therapy after surgery
After surgery, systemic therapy may be indicated to remove microscopic cells that are not seen in images. The choice between chemotherapy, hormone therapy, or targeted therapies depends on the tumor profile (hormone receptors, HER2, grade, size, and nodes).
This stage of treatment focuses on reducing the risk of relapse and, when appropriate, is accompanied by radiation therapy if lumpectomy has occurred or if there are risk factors after mastectomy.
Approach to stage III breast cancer
Neoadjuvant therapy prior to surgery
In stage III, with large tumors or involved lymph nodes, it is common to start neoadjuvant treatment. The goal is to shrink the tumor and increase the chance of less extensive surgery.
Another key point is that it allows the actual response of the tumour to be observed while it is being treated. This response guides adjustments in the subsequent plan, and in some cases helps to decide the type of surgery and the need for additional treatments.
Radiation therapy after surgery
Radiation therapy is indicated to treat the operated area and, when appropriate, the regional lymph nodes. It is standard after lumpectomy and is assessed after mastectomy according to tumor size, lymph nodes and margins.
Planning is adjusted to the anatomy and extent of the disease, seeking good local control with an acceptable side effect profile.
Systemic Treatment Options Based on Tumor Profile
Chemotherapy: When It’s Needed
Chemotherapy is indicated when the risk of recurrence is high according to stage, tumor grade, lymph nodes, and biomarkers. It is usually common in triple-negative tumors and in many HER2-positive tumors (in combination with targeted therapies).
The choice of regimen depends on expected efficacy, toxicity, and medical conditions. It is not just a matter of “giving chemotherapy”, but of choosing the intensity that the patient can tolerate and that really provides benefit.
Hormone therapy in receptor-positive tumors
In hormone receptor-positive tumors, hormone therapy blocks or reduces estrogen stimulation. The typical duration ranges from 5 to 10 years, depending on individual risk and tolerance.
The type of hormone therapy is selected based on menopausal status and other factors, and side effects such as joint symptoms, hot flashes, or changes in bone health are monitored.
Biomarker-guided targeted therapies
Targeted therapies target alterations such as HER2 or other mutations. In HER2-positive breast cancer, these strategies have changed the natural history of the disease.
There are also subgroups with changes such as PIK3CA where there may be targeted alternatives. That is why biomarkers are not a “detail”: they guide specific options and avoid treatments that are unlikely to work.
Immunotherapy in selected cases
Immunotherapy seeks to activate the immune system against the tumor. It is mainly used in advanced or metastatic triple-negative breast cancer, and is usually combined with chemotherapy.
Not all patients are candidates. The tumor profile and clinical context are assessed, because immunotherapy can bring immunological side effects that require close monitoring.
Treatment of Metastatic Breast Cancer
Continuous evaluation and adjustment of treatment lines
In metastatic breast cancer, the strategy changes: it seeks to control the disease, relieve symptoms and sustain quality of life. This requires constant follow-up with clinical evaluation and studies, and adjustments when there is insufficient response or progression.
The sequence of treatments is adapted according to biomarkers, location of metastasis, previous treatments and tolerance. Systemic therapy is usually the axis, with local interventions when they provide control or relief.
Clinical trials as a therapeutic alternative
Clinical trials can offer access to innovative treatments. They are considered when the tumor does not respond as expected or when standard options have been exhausted.
Participation depends on study criteria, biomarkers and clinical situation. In any case, it explains what is expected, what controls are required and what risks exist.
The multidisciplinary team and the coordination of treatment
Role of the tumor committee
Complex decisions are often discussed in a tumor committee, involving medical oncology, surgery, radiology, pathology, and radiation therapy. This exchange helps integrate biopsy findings, imaging, and therapeutic goals.
It is especially useful when there are equivalent options, when the stage is “borderline”, or when the lymph nodes raise questions about the best order between surgery and neoadjuvant treatment.
Communication between specialists and patient
The patient needs clear information: what is known about the tumor, what is not yet known, and what is gained with each step. When communication is good, adherence to treatment improves and anxiety generated by plan changes is reduced.
There is also talk of follow-up with mammography and ultrasound when appropriate, and self-care measures. Self-examination can serve as a support to detect new changes, although it does not replace professional controls.
Frequently Asked Questions (FAQs)
¿Siempre se necesita quimioterapia en cáncer de mama?
No. It depends on the stage, lymph nodes, hormone receptors, HER2, and genomic testing. In tumors with positive receptors and low risk, hormone therapy may be the axis and chemotherapy may not provide a relevant benefit.
¿Cuánto dura el tratamiento completo?
It varies by stage and type of tumor. Surgery and radiation therapy are completed in weeks or a few months, while hormone therapy is usually maintained for years (common 5 to 10). In metastatic breast cancer, treatment is organized by lines according to response.
¿Qué efectos secundarios se pueden esperar?
They change according to the plan. Surgery can cause pain and time limitation; Radiation therapy can irritate the skin and make you tired; chemotherapy can cause nausea, hair loss and low defenses; Hormone therapy can cause hot flashes or joint discomfort. The medical team adjusts supportive measures to reduce side effects and maintain treatment.
¿Se puede preservar la fertilidad durante el tratamiento?
In women of reproductive age, it is discussed early because some therapies can affect ovaries. There are preservation options that require coordination with specialists and defined times, so it is advisable to consider it from the beginning of the plan.
¿Qué papel tienen los biomarcadores en la elección del tratamiento?
Biomarkers (hormone receptors, HER2, and genomic signatures) help choose therapies that are more likely to work and avoid unnecessary treatments. They are decisive in deciding hormone therapy, targeted therapies, immunotherapy and the intensity of chemotherapy.
¿Qué controles se hacen durante y después del tratamiento?
Periodic consultations, laboratory tests according to the scheme and imaging studies are carried out when indicated. At follow-up, mammography and ultrasound are ordered depending on the type of surgery and risk, along with clinical evaluation.
¿Cuándo conviene pensar en ensayos clínicos?
When the case is advanced, when metastatic breast cancer progresses after one or more lines of treatment, or when there are biomarkers that fit with an available protocol. American Society of Clinical Oncology Says Shared Decision-Making Improves Outcomes
Precision medicine continues to expand alternatives and allows the plan to be adjusted more accurately. International clinical studies also support that adapting the strategy to the tumour profile can improve survival and quality of life. In daily practice, the most important thing is to integrate testing, stage, treatment response, and personal priorities, with close follow-up and clear communication.
With a confirmed diagnosis, the plan is not improvised: it is put together step by step and reviewed every time new clinical or biopsy information appears. This way of working reduces unnecessary interventions and focuses resources on what really brings benefit. How is personalized treatment decided in patients with breast cancer? It is decided by integrating stage, biomarkers, general health and preferences, to choose the therapy with the best balance between disease control and quality of life.
